- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14:36 | Silexion Therapeutics Corp: Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204 | 52 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 12.02. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 30.01. | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | 1.259 | AFX News | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| 29.01. | Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds | 15 | Seeking Alpha | ||
| 29.01. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds | 5 | GlobeNewswire (USA) | ||
| 29.01. | HotStocks USA: +60 % bei Silexion Therapeutics | 14 | stock3.com | ||
| 29.01. | Pre-market Movers: Silexion Therapeutics, Zentalis Pharmaceuticals, 60 Degrees Pharmaceuticals, Manhattan Associates, Nextracker | 410 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Silexion Therapeutics Corp (SLXN) is up over 65%... ► Artikel lesen | |
| 28.01. | Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday? | 18 | Benzinga.com | ||
| 28.01. | Silexion reports breakthrough in KRAS cancer therapy | 1 | Investing.com | ||
| 28.01. | Silexion meldet Durchbruch in KRAS-Krebstherapie | 13 | Investing.com Deutsch | ||
| 28.01. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 16.01. | Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies | 3 | Benzinga.com | ||
| 16.01. | Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session | 5 | Benzinga.com | ||
| 16.01. | Silexion Therapeutics drops 18%, prices $5M share offering | 3 | Seeking Alpha | ||
| 16.01. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 15.01. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies | 129 | GlobeNewswire (Europe) | Cayman Islands, January 15, 2025 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers... ► Artikel lesen | |
| 14.01. | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.01. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 13.01. | Silexion Therapeutics Corp: Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium | 2 | GlobeNewswire (USA) | ||
| 10.01. | SLXN-Aktie fällt auf 52-Wochen-Tief von 1,82 US-Dollar | 6 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,798 | -3,93 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| PALATIN TECHNOLOGIES | 0,890 | -3,05 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 17.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.02.2025ISIN NameCA00208E3077 ATI... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
| VERASTEM | 5,200 | -2,80 % | Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates | BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | XFRA YP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOLINERX LTD. DL-... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative... ► Artikel lesen | |
| QUANTUM-SI | 1,460 | -9,60 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,448 | -2,18 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study | 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 4,400 | -34,81 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial | No significant safety or dose limiting toxicities reported
PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Feb.... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 1,170 | -4,88 % | Psyence Biomedical Ltd.: Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements | NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that... ► Artikel lesen | |
| MINK THERAPEUTICS | 9,410 | -9,52 % | MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting | NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural... ► Artikel lesen | |
| QIAGEN | 37,675 | -1,62 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch... ► Artikel lesen | |
| TEMPUS AI | 59,07 | -15,08 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| EVOTEC | 8,285 | -3,61 % | Evotec-Aktie heute gut behauptet: Aktienwert steigt (8,985 €) | Im Plus liegt zur Stunde der Anteilsschein von Evotec . Der jüngste Kurs betrug 8,99 Euro. An der Börse liegt die Evotec-Aktie aktuell im Plus. Das Wertpapier legte um 22 Cent zu. Für das Papier liegt... ► Artikel lesen |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,390 (+46,43 %) liegt der Kurs bei 1,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.
